HP 228: Started a Phase II trial in 16 patients who will receive one of two fixed doses delivered iv.

Houghten Pharmaceuticals Inc. (HPIP), San Diego, Calif. Product: HP 228, small molecule cytokine regulating agent Indication: Obese patients with non-insulin-dependent diabetes mellitus Status: Starte...